痛泻安肠方治疗肝郁脾虚型腹泻型肠易激综合征临床观察

Tongxie Anchang Recipe in the Treatment of Diarrhea-type Irritable Bowel Syndrome of Liver Stagnation and Spleen Deficiency Type

目的明确痛泻安肠方对肝郁脾虚型腹泻型肠易激综合征(IBS-D)的临床疗效和治疗优势。方法采用单中心、随机、阳性药物对照的临床设计开展探索性研究。共纳入36例肝郁脾虚型IBS-D患者,分为2组,每组18例;治疗组予痛泻安肠方,对照组予阳性对照药匹维溴铵片,2组疗程均为4周。观察2组疗效指标和安全性指标。结果治疗组肠易激综合征严重程度评测(IBS-SSS)总评分和中医证候评分低于对照组(P<0.05)。治疗组改善IBS-SSS总有效率、中医证候疗效总有效率为88.89%(16/18)、83.33%(15/18),略高于对照组的83.33%(15/18)、77.78%(14/18),差异无统计学意义(P>0.05)。此外,2组均无明显不良反应发生,安全性检查未见明显异常。结论痛泻安肠方治疗肝郁脾虚型IBS-D安全有效,在改善患者症状方面具有更好的效果。

Objective To clarify the clinical curative effect and therapeutic advantage of Tongxie Anchang recipe in treating diarrheal-type irritable bowel syndrome(IBS-D)of liver stagnation and spleen deficiency type.Methods An exploratory study was conducted us⁃ing a single-center,randomized,positive drug control clinical design.A total of 36 patients with (IBS-D)of liver stagnation and spleen deficiency type were included and divided into 2 groups,with 18 cases in each group.The treatment group was given Tongxie Anchang recipe,and the control group was given Piverium bromide tablet.The treatment course of both groups was 4 weeks.The efficacy in⁃dexes and safety indexes of 2 groups were observed.Results The total score of IBS severity evaluation(IBS-SSS)and TCM syndrome score in the treatment group were lower than those in the control group(P<0.05).The total effective rate of improved IBS-SSS and TCM syndromes in the treatment group were 88.89%(16/18)and 83.33%(15/18),which were slightly higher than those in the control group(83.33%,15/18 and 77.78%,14/18),and there was no statistical significance(P>0.05).In addition,no obvious adverse reac⁃tions occurred in both groups,and no obvious abnormalities were found in safety tests.Conclusion Tongxie Anchang recipe is safe and effective in the treatment of IBS-D of liver stagnation and spleen deficiency type,and it has better efficacy in improving anxiety and tension in patients.